EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease

Nicole Wagner iD, Kay-Dietrich Wagner iD

International Journal of Molecular Sciences · 25.01.2023 · 24 (3) · 2345

DOI: 10.3390/ijms24032345 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.01.2023. Verfasst von Nicole Wagner und 1 weiteren Autor:innen. Beteiligte Einrichtung: CNRS, INSERM, Université Côte d'Azur, iBV, 06107 Nice, France. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases, PPAR-beta. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation pour la Recherche Medicale, Fondation ARC pour la recherche sur le cancer”, Gemluc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peroxisome proliferator activated receptors, including PPARα, PPARβ/δ, and PPARγ, are ligand-activated transcription factors belonging to the nuclear receptor superfamily. They play important roles in glucose and lipid metabolism and are also supposed to reduce inflammation and atherosclerosis. All PPARs are involved in angiogenesis, a process critically involved in cardiovascular pathology. Synthetic specific agonists exist for all PPARs. PPARα agonists (fibrates) are used to treat dyslipidemia by decreasing triglyceride and increasing high-density lipoprotein (HDL) levels. PPARγ agonists (thiazolidinediones) are used to treat Type 2 diabetes mellitus by improving insulin sensitivity. PPARα/γ (dual) agonists are supposed to treat both pathological conditions at once. In contrast, PPARβ/δ agonists are not in clinical use. Although activators of PPARs were initially considered to have favorable effects on the risk factors for cardiovascular disease, their cardiovascular safety is controversial. Here, we discuss the implications of PPARs in vascular biology regarding cardiac pathology and focus on the outcomes of clinical studies evaluating their benefits in cardiovascular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Cardiovascular DiseasesPPAR-betaHumansPeroxisome Proliferator-Activated ReceptorsPPAR gammaPPAR alpha

Stichwörter der Autor:innen

angiogenesisangiotensin receptor blockersangiotensin-converting enzyme inhibitorsaspirincardiovascular diseaseclinical trialsmyocardial infarctionperoxisome proliferator activated receptorsstatins

Substanzen

Peroxisome Proliferator-Activated ReceptorsPPAR gammaPPAR alphaPPAR-beta

Autor:innen und Institutionen

  • CNRS, INSERM, Université Côte d'Azur, iBV, 06107 Nice, France.

ORCID-Profile: Nicole Wagner, Kay-Dietrich Wagner

Förderung

  • Fondation pour la Recherche Medicale
  • Fondation ARC pour la recherche sur le cancer”
  • Gemluc
  • Plan Cancer INSERM

Zitieren

APA

Wagner, N., & Wagner, K. D. (2023). Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease. International Journal of Molecular Sciences, 24(3), 2345. https://doi.org/10.3390/ijms24032345

Vancouver

Wagner N, Wagner KD. Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease. International Journal of Molecular Sciences. 2023;24(3):2345. doi:10.3390/ijms24032345

BibTeX
@article{Wagner2023,
  author = {Wagner, Nicole and Wagner, Kay-Dietrich},
  title = {Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {2345},
  doi = {10.3390/ijms24032345}
}
Kostenlos starten →